WANBURY
|
WANBURY Last 5 Year Financial Ratios History
[Consolidated]
| Mar2024 | Mar2023 | Mar2022 | Mar2021 | Mar2020 | |
|---|---|---|---|---|---|
| Operational & Financial Ratios | |||||
| Earnings Per Share (Rs) | 17.09 | -3.18 | 24.94 | -5.04 | 25.79 |
| CEPS(Rs) | 21.07 | 0.61 | 28.45 | -1.14 | 29.66 |
| DPS(Rs) | - | - | - | - | - |
| Book NAV/Share(Rs) | 6.44 | -10.57 | -7.55 | -62.60 | -57.48 |
| Tax Rate(%) | 0.68 | -1.06 | -0.43 | -1.61 | 0.32 |
| Margin Ratios | |||||
| Core EBITDA Margin(%) | 12.05 | 4.53 | 6.17 | 3.97 | -5.83 |
| EBIT Margin(%) | 14.72 | 2.18 | 19.77 | 2.71 | 26.30 |
| Pre Tax Margin(%) | 9.70 | -2.02 | 15.77 | -3.15 | 17.44 |
| PAT Margin (%) | 9.63 | -2.04 | 15.83 | -3.20 | 17.38 |
| Cash Profit Margin (%) | 11.88 | 0.39 | 18.06 | -0.72 | 19.99 |
| Performance Ratios | |||||
| ROA(%) | 17.60 | -3.22 | 25.85 | -4.51 | 23.10 |
| ROE(%) | - | - | - | - | - |
| ROCE(%) | 101.15 | 29.82 | 428.78 | 87.61 | 444.45 |
| Asset Turnover(x) | 1.83 | 1.58 | 1.63 | 1.41 | 1.33 |
| Sales/Fixed Asset(x) | 2.38 | 2.18 | 2.32 | 1.88 | 1.83 |
| Working Capital/Sales(x) | -10.60 | -2.57 | -2.73 | -1.53 | -1.71 |
| Efficiency Ratios | |||||
| Fixed Capital/Sales(x) | 0.42 | 0.46 | 0.43 | 0.53 | 0.55 |
| Receivable days | 49.78 | 47.23 | 34.50 | 39.45 | 46.85 |
| Inventory Days | 18.23 | 25.70 | 26.45 | 17.17 | 15.54 |
| Payable days | 187.82 | 197.43 | 190.42 | 210.79 | 243.11 |
| Valuation Parameters | |||||
| PER(x) | 8.54 | - | 3.41 | - | 0.71 |
| PCE(x) | 6.92 | 61.38 | 2.99 | -72.77 | 0.61 |
| Price/Book(x) | 22.63 | -3.53 | -11.25 | -1.33 | -0.32 |
| Yield(%) | - | - | - | - | - |
| EV/Net Sales(x) | 1.01 | 0.36 | 0.62 | 0.91 | 0.52 |
| EV/Core EBITDA(x) | 7.97 | 7.57 | 8.67 | 17.44 | 7.83 |
| EV/EBIT(x) | 6.80 | 16.41 | 3.14 | 33.39 | 1.97 |
| EV/CE(x) | 4.22 | 5.84 | 0.92 | 1.26 | 0.70 |
| M Cap / Sales | 0.83 | 0.24 | 0.54 | 0.53 | 0.12 |
| Growth Ratio | |||||
| Net Sales Growth(%) | 15.21 | -2.26 | 30.23 | 6.82 | -6.11 |
| Core EBITDA Growth(%) | 203.06 | -34.59 | 80.29 | -16.93 | -1.14 |
| EBIT Growth(%) | 669.96 | -89.08 | 853.58 | -89.06 | 554.63 |
| PAT Growth(%) | 638.26 | -112.76 | 746.33 | -119.56 | 359.43 |
| EPS Growth(%) | 637.60 | -112.74 | 594.95 | -119.54 | 346.19 |
| Financial Stability Ratios | |||||
| Total Debt/Equity(x) | 5.21 | -1.86 | -2.72 | -1.02 | -1.14 |
| Current Ratio(x) | 0.74 | 0.38 | 0.48 | 0.27 | 0.30 |
| Quick Ratio(x) | 0.58 | 0.31 | 0.34 | 0.20 | 0.26 |
| Interest Cover(x) | 2.93 | 0.52 | 4.94 | 0.46 | 2.97 |
| Total Debt/Mcap(x) | 0.23 | 0.53 | 0.24 | 0.77 | 3.60 |
Compare Financial Ratios of peers of WANBURY
| Peers & Returns | Market Capitalization | 1 Week | 1 Month | 1 Year | ||
| WANBURY | ₹969.9 Cr | 8.2% | 18.7% | 111.6% | Stock Analytics | |
| SUN PHARMACEUTICAL INDUSTRIES | ₹453,426.0 Cr | 3.7% | 5.8% | 50.4% | Stock Analytics | |
| DIVIS LABORATORIES | ₹161,165.0 Cr | 5.5% | -1.2% | 56% | Stock Analytics | |
| CIPLA | ₹123,634.0 Cr | 3.6% | -0.3% | 22.7% | Stock Analytics | |
| DR REDDYS LABORATORIES | ₹114,274.0 Cr | 2.7% | 15.5% | 20.6% | Stock Analytics | |
| ZYDUS LIFESCIENCES | ₹97,972.0 Cr | 0.7% | 0.6% | 39.1% | Stock Analytics | |
WANBURY Share Price vs Sensex
| Share Price Returns(%) | 1 Week | 1 Month | 1 Year |
| WANBURY | 8.2% |
18.7% |
111.6% |
| SENSEX | 0% |
-1.6% |
9% |
You may also like the below Video Courses
